CLAIMS

1. Use of a composition comprising live bacteria selected from the group consisting of bacteria of the family *Erysipelotrichaceae* except those of the genus *Solobacterium*, bacteria of the family *Rikenellaceae,* bacteria of the class *Negativicutes,* bacteria of the order *Selenomonadales,* bacteria of the species *Bacteroides fragilis* and mixtures thereof, in the manufacture of a medicament for the treatment of colorectal cancer (CRC) in a human patient, wherein said medicament is to be administered to the patient in a way that enables the delivery of live bacteria to the ileum, and wherein said composition is to be administered to a patient receiving an oxaliplatin-based therapy.

2. The use of claim 1, wherein said composition comprises live bacteria selected from the group consisting of *Erysipelothrix tonsillarum*, *Erysipelatoclostridium ramosum*, *Alistipes onderdonkii* and mixtures thereof.

3. The use of claim 1, wherein said composition further comprises bacteria selected from the group consisting of bacteria of the order *Lactobacillales, Prevotella copri*, *Faecalibacterium prausnitzii* and mixtures thereof.

4. The use of claim 1, wherein said composition is to be administered to a patient receiving a neoadjuvant oxaliplatin-based therapy.

5. The use of claim 1, wherein said composition is to be administered to a patient receiving an immunotherapy, preferably PD-1/PDL1 blockade or anti-Lag3 Ab, in combination with said oxaliplatin-based chemotherapy.